IMPORTANT ARATANA THERAPEUTICS, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the Southern District of New York against Aratana Therapeutics, Inc.

NEW YORK, Feb. 09, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces  that  a  securities class  action  lawsuit  has  been  filed  against  Aratana Therapeutics, Inc. (“Aratana”  or the “Company”)  (Nasdaq:PETX) in the  United States District  Court for  the Southern  District of  New York  on behalf  of persons or entities who purchased or otherwise acquired Aratana stock  between March 16,  2015 through  February  3, 2017,  inclusive (the  “Class  Period”). 

Investors who have incurred losses in shares of  Aratana Therapeutics, Inc. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If   you  have  purchased  shares of Aratana Therapeutics, Inc. within  the class period, you may, no later than April 7, 2017, request that the Court appoint you lead plaintiff of the proposed class.

Aratana Therapeutics, Inc. is a development-stage biopharmaceutical company that develops biomedical therapeutics for animals. The Company offers various products to treat pain and inflammation associated with serious medical conditions in pets. One of the Company’s key products is ENTYCE, also known as AT-002 (capromorelin oral solution), an appetite stimulant for dogs.

The filed Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (ii) consequently, ENTYCE was not likely to be commercially available until late 2017; (iii) accordingly, Aratana had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and (iv) as a result of the foregoing, Aratana’s public statements were materially false and misleading at all relevant times.   

On February 6, 2017, Aratana disclosed that the Center for Veterinary Medicine (“CVM”) had requested more information about ENTYCE.  Aratana advised investors that the CVM’s request was “in connection with the Company’s post-approval supplement request to transfer the manufacturing of ENTYCE to a new vendor in order to produce ENTYCE at a commercial scale” and that the Company “now anticipates that ENTYCE . . . will be commercially available by late 2017.”

On this news, Aratana’s share price fell $1.44, or 17.93%, to close at $6.59 on February 6, 2017.

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Patrick Donovan, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.